Hints and tips:
Related Special Reports
...Timothy Mackey, professor of global health at University of California San Diego, predicted that other pharma companies would probably follow Eli Lilly and Pfizer....
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...Pfizer’s chief executive Albert Bourla said on the company’s most recent earnings call that it would have much more clarity and certainty about the future of its Covid products by the end of the year....
...Because the European market is saturated with the BioNTech/Pfizer and Moderna shots, it remains unclear what impact on its revenues an approval might have....
...The early-stage plans are the latest effort by a pharmaceutical company to circumvent industry middlemen and sell drugs directly to US patients....
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...The partnership strengthens Sanofi, one of the world’s largest vaccine makers by sales, in the post-pandemic Covid jab market, where pharmaceutical groups are increasingly focused on combined shots against...
...Vaccine hopes and demand for medical treatments also buoyed pharmaceutical groups such as Moderna and Pfizer in 2020, as well as lesser-known Chinese groups, including WuXi Biologics, Chongqing Zhifei Biological...
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Shah Capital now owns 6.7 per cent of Novavax, having first bought into the company in the last quarter of 2022....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...Pfizer shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid...
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...Albert Bourla, Pfizer’s chief executive, said the company’s product portfolio, apart from Covid medicines, remained strong, with the company expecting revenues from the rest of the business to grow between...
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Roche plans to buy immunology company Telavant from Roivant Sciences and Pfizer for more than $7bn, as the drugmaker’s new chief executive seeks to replenish its drug pipeline....
...In a separate action on Thursday, four men were arrested for engaging in an $2.2mn insider trading scheme over a merger of two pharmaceutical companies in 2020....
...The California-based pharmaceutical company agreed to the acquisition in December last year, winning a three-way race to add a new pipeline of drugs for rare autoimmune and inflammatory diseases....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...He said chancellor Jeremy Hunt and the health department should address conflicts with the pharmaceutical industry over drug prices and hurdles to running clinical trials in the NHS....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
International Edition